RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines by Rashmi Narendrula et al.
RESEARCH ARTICLE Open Access
RNA disruption is associated with response
to multiple classes of chemotherapy drugs
in tumor cell lines
Rashmi Narendrula1, Kyle Mispel-Beyer2, Baoqing Guo4,6, Amadeo M. Parissenti1,2,3,4,5,6, Laura B. Pritzker6,
Ken Pritzker6, Twinkle Masilamani6, Xiaohui Wang6 and Carita Lannér1,2,3*
Abstract
Background: Cellular stressors and apoptosis-inducing agents have been shown to induce ribosomal RNA (rRNA)
degradation in eukaryotic cells. Recently, RNA degradation in vivo was observed in patients with locally advanced
breast cancer, where mid-treatment tumor RNA degradation was associated with complete tumor destruction and
enhanced patient survival. However, it is not clear how widespread chemotherapy induced “RNA disruption” is, the
extent to which it is associated with drug response or what the underlying mechanisms are.
Methods: Ovarian (A2780, CaOV3) and breast (MDA-MB-231, MCF-7, BT474, SKBR3) cancer cell lines were treated
with several cytotoxic chemotherapy drugs and total RNA was isolated. RNA was also prepared from docetaxel
resistant A2780DXL and carboplatin resistant A2780CBN cells following drug exposure. Disruption of RNA was
analyzed by capillary electrophoresis. Northern blotting was performed using probes complementary to the 28S
and 18S rRNA to determine the origins of degradation bands. Apoptosis activation was assessed by flow cytometric
monitoring of annexin-V and propidium iodide (PI) binding to cells and by measuring caspase-3 activation. The link
between apoptosis and RNA degradation (disruption) was investigated using a caspase-3 inhibitor.
Results: All chemotherapy drugs tested were capable of inducing similar RNA disruption patterns. Docetaxel
treatment of the resistant A2780DXL cells and carboplatin treatment of the A2780CBN cells did not result in RNA
disruption. Northern blotting indicated that two RNA disruption bands were derived from the 3’-end of the 28S
rRNA. Annexin-V and PI staining of docetaxel treated cells, along with assessment of caspase-3 activation, showed
concurrent initiation of apoptosis and RNA disruption, while inhibition of caspase-3 activity significantly reduced
RNA disruption.
Conclusions: Supporting the in vivo evidence, our results demonstrate that RNA disruption is induced by multiple
chemotherapy agents in cell lines from different tissues and is associated with drug response. Although present,
the link between apoptosis and RNA disruption is not completely understood. Evaluation of RNA disruption is thus
proposed as a novel and effective biomarker to assess response to chemotherapy drugs in vitro and in vivo.
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Background
Control of cellular RNA degradation
RNA molecules play critical roles in cells, including the
facilitation of protein synthesis and regulation of gene
expression. To prevent errors in the biosynthesis and
function of cellular RNAs, quality control surveillance
mechanisms have evolved to identify and preferentially
degrade aberrant or nonfunctional RNAs. Degradation
of nonfunctional RNAs occurs in regulated stages and
involves specialized mechanisms [1]. Mechanisms of
controlled RNA degradation exist for messenger RNA
(mRNA), transfer RNA (tRNA) and for ribosomal RNA
(rRNA) [2–9]. The active components of RNA degradation
mechanisms typically include RNA-degrading enzymes or
RNases, which interact with numerous co-factors (heli-
cases, polymerases, ubiquitylases, and chaperone proteins)
to provide specificity to each type of process.
Apoptosis and rRNA degradation
The degradation of DNA into internucleosomal fragments
is a well-known hallmark of apoptosis [10]. Although not
as well-characterized, numerous studies have shown that
rRNA may also be degraded, in conjunction with apop-
tosis, into specific-sized fragments derived from the 28S
and/or 18S rRNAs. Early studies demonstrated that both
cytotoxic and apoptosis-inducing agents can induce rRNA
fragmentation and apoptosis, in a variety of cell lines
and types [11–14]. The phenomenon is widespread,
also occurring in plants, like oats [15]. Mroczek and
Kufel [16] have used the term “stress-induced rRNA
fragmentation” to describe the phenomenon by which
various cellular stressors activate programmed cell death
pathways in yeast, some of which are associated with
rRNA degradation. However, the apparent connection
between apoptosis and rRNA degradation is not com-
pulsory, as it was shown that rRNA cleavage could
occur in the absence of caspase- and BCL-2 dependent
apoptosis [17].
Chemotherapy-dependent “RNA disruption”
Although apoptosis-inducing agents have been shown
to induce rRNA degradation in mammalian cells, other
cytotoxic agents, such as chemotherapy drugs, have not
yet been investigated in this respect. Recently, image-
guided tumor core biopsies were taken from patients
with locally advanced or inflammatory breast cancer
enrolled in the CAN-NCIC-MA.22 clinical trial [18].
Samples were taken prior to, during, and post-treatment
with an epirubicin/docetaxel combination chemotherapy.
Tumor levels of several biomarkers, including RNA, were
then assessed for their relationship to treatment response
[18]. Interestingly, a significant association was observed
between mid-treatment RNA degradation [19] and the
absence of tumor cells in the breast and axilla after
treatment (pathologic complete response). The RNA deg-
radation bands were generally of high molecular weight,
considerably greater than that observed during autolytic
degradation of RNA in tissue samples [19]. These high
molecular weight bands were observed following 8–18
weeks of chemotherapy treatment [18]. We refer to this
ability of chemotherapy agents to induce long-lived rRNA
fragments typically not seen after extensive autolytic
degradation as “RNA disruption”. Since the RIN algorithm
specifically quantifies the formation of low molecular
weight autolytic RNA degradation products [19] and since
abnormal RNA banding patterns during RNA disruption
results in the assignment of “n/a” values for RIN by the
Agilent Bioanalyzer, we recently developed the RNA
disruption assay (RDA), which quantifies RNA disruption
in tumors and tumor cells as an RNA disruption index
(RDI), and is a ratio of abnormal to normal rRNAs [20].
Chemotherapy treatment in the above clinical trial was
also found to be associated with reduced tumor RNA
content in patients, which may be attributed to both
the observed RNA degradation and a suppression of
RNA synthesis in tumor cells [20]. Moreover, the above
study demonstrated that high tumor RNA disruption
mid-treatment was associated with markedly enhanced
disease-free survival post-chemotherapy. Our observa-
tions of reduced RNA content in patient tumors upon
chemotherapy treatment were also consistent with pre-
viously published studies indicating that numerous
cytotoxic chemotherapeutic drugs can strongly interfere
with ribosome biogenesis [21, 22].
In the current study, we describe for the first time an in
vitro cell model system for the study of chemotherapy-
dependent RNA disruption. This included an investigation
into the relationship between RNA disruption, drug type,
drug dose, and drug incubation time. We also examined
whether RNA disruption reflected the sensitivity of cells
to various drugs (previously measured using the clono-
genic assay). In addition, we explored the origins of the
rRNA fragments and the temporal relationship between
the induction of apoptosis by docetaxel, as measured
by enhanced caspase activity and annexin V staining,
and RNA disruption. Finally, we show that inhibition
of caspase-3 activity reduces, but does not eliminate,
RNA disruption in response to docetaxel.
Methods
This study did not require ethics approval from an ethics
review committee or board because the study did not
involve animals, humans, human data or material dir-
ectly collected from humans or animals.
Cell culture
The A2780 parental cell line was acquired from the
European Collection of Cell Cultures. The development
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and characterization of the docetaxel-resistant A2780DXL
and carboplatin-resistant A2780CBN cell lines used in
this study were described previously [23]. Cell lines
were maintained in RPMI-1640 culture medium con-
taining 10 % FBS, 1 % penicillin (10,000 units/ml),
and 1 % streptomycin (10,000 μg/ml) (Hyclone La-
boratories, Logan, UT, USA). Docetaxel resistance in
the A2780DXL cell line was maintained by treating
the cells with 0.4 μM docetaxel in complete medium
weekly. Carboplatin resistance in A2780CBN cells was
similarly maintained by treating the cells with 22 μM
carboplatin. The CaOV3 and MCF-7 cell lines, a gift
from Dr. Linda Malkas, were maintained in DMEM
containing 10 % FBS, 1 % penicillin (10,000 units/ml),
and 1 % streptomycin (10,000 μg/ml) (Hyclone La-
boratories, Logan, UT, USA). The SKBR3 and BT474
cell lines, a gift from Dr. Robert Lafrenie, were also
maintained in DMEM containing 10 % FBS, 1 % penicillin
(10,000 units/ml), and 1 % streptomycin (10,000 μg/ml)
(Hyclone Laboratories, Logan, UT, USA). The MDA-MB-
231 cell line was purchased from the American Type
Culture Collection (Manassas, VA, USA) and was main-
tained in RPMI containing 10 % FBS, 1 % penicillin
(10,000 units/ml), and 1 % streptomycin (10,000 μg/ml)
(Hyclone Laboratories, Logan, UT, USA). Chemotherapy
drugs (docetaxel, paclitaxel, carboplatin, cisplatin, vin-
cristine, etoposide, irinotecan, doxorubicin) were ac-
quired from the pharmacy at Health Sciences North,
Sudbury, Ontario, Canada.
Dose and time exposure experiments
To assess the effect of drug dose on RNA disruption,
cells were seeded into six-well plates for 24 h, following
which each well was exposed to increasing doses of
paclitaxel, docetaxel or carboplatin. After determining
the most effective doses to induce RNA disruption, time
exposure experiments were performed where cell cul-
tures were exposed to specific drug doses for varying
amounts of time (e.g. 24, 48, 72 h). Replicate experi-
ments were performed at least three times.
RNA isolation and integrity analysis
Cells were harvested by scraping the adherent cells in
lysis buffer and collecting them, along with any floating
cells by centrifugation. Total RNA was isolated from har-
vested cells using miRNeasy kits (Qiagen Inc., Toronto,
ON, CA). The quantity and integrity of isolated RNA
was determined by capillary electrophoresis on an Agi-
lent 2100 Bioanalyzer (Agilent Technologies Canada,
Inc., Mississauga, ON, CA) with known reference RNA
standards of various masses. The RNA Disruption
Index (RDI) was calculated for each sample using a
proprietary algorithm (RNA Diagnostics, Inc., Toronto,
ON, CA), which computes the ratio of abnormal to
normal rRNAs [20].
Northern blot analysis
Total RNA was isolated from A2780 cells treated with
or without 0.2 μM docetaxel for 48 h. The component
RNAs (5 μg per lane) were resolved by denaturing for-
maldehyde 1 % agarose gel electrophoresis, transferred
to BioTrace PVDF membranes (Life Sciences, Pensacola,
FL, USA), and UV cross-linked. The membranes were
then incubated with various radiolabeled probes hybrid-
izing to sequences within the 28S and 18S rRNAs. These
probes (Table 1) were derived from rRNA probes de-
scribed in publications by He et al. [24], Houge et al.
[12] and Nadano et al. [25]. The alignment of all probe
sequences were checked against human rRNA sequences
(28S rRNA: Genbank ID M11167.1; 18S rRNA: Genbank
ID M10098.1) to ensure complete sequence homology.
Probes were labeled using γ-32P-ATP and the DNA
5’ End Labeling System by Promega (Fisher Scientific,
Mississauga, ON, CA). Hybridization was performed
according to Brown and Mackey [26]. Following
hybridization and washing, blots were sealed in bags
and exposed to phosphor imaging screens for various
lengths of time. Screens were scanned using a Bio-
Rad Molecular Imager FX (Bio-Rad Laboratories, Ltd.,
Mississauga, ON, CA). Band sizes were determined
using Quantity One software from Bio-Rad Laborator-
ies, Inc.
Flow cytometry experiments
To analyze the effect of docetaxel on the proportion of
cells entering apoptosis, cells were stained with annexin
V and propidium iodide (PI) (CytoGLO Annexin V-FTIC
Apoptosis Kit, IMGENEX, San Diego, CA, USA) and the
percentage of apoptotic cells (annexin V positive, PI nega-
tive) was determined by flow cytometry on a BD FACS
Canto II flow cytometer (Becton-Dickinson Biosciences,
Mississauga, ON, CA). The effect of docetaxel on cell
cycle progression was also assessed by flow cytometry
after cells were fixed and stained with PI alone as de-
scribed previously [27].
Caspase activity and inhibition assays
Caspase-3 activity in extracts of control and docetaxel-
treated cells was assayed by monitoring cleavage of a
DEVD substrate using the CPP32 Colorimetric Assay
Kit from BioVision Inc. (Milpitas, CA, USA). The effects
of caspase-3 inhibition on docetaxel-induced caspase
activity and docetaxel-dependent RNA disruption were
determined by treating cells with and without docetaxel
and/or the caspase-3 inhibitor, Q-DEVD-Oph (BioVision
Inc., Milpitas, CA, USA), and then assaying extracts of
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these cells for caspase-3 activity and RNA disruption as
described above.
Statistical analysis
Statistical analyses were performed using Microsoft Excel
or GraphPad Prism 5 software and differences with p <
0.05 were considered statistically significant. Significance
was determined using a two-way ANOVA with Bonferroni
post-hoc test when comparing two variables. A one-tailed
t-test was performed to determine the impact of increas-
ing carboplatin concentration on cellular RDI values. For
all other data, a two-tailed t-test was performed after
application of the F-test to determine equality of variance.
Results
Taxane-induced RNA disruption in A2780 and CaOV3 cells
is both dose- and time-dependent
RNA disruption in A2780 cell cultures became evident
at a dose of 0.005 μM for both docetaxel and paclitaxel,
but peaked at 0.2 and 1 μM for these drugs, respectively.
RNA disruption was evident in the taxane-treated cells
by the presence of abnormal bands on the electrophero-
gram, distinct from the normal RNA banding pattern
seen in untreated cells (Fig. 1a and c). Furthermore, a
significant decrease in total cellular RNA content was
also observed upon chemotherapy treatment (Additional
file 1). To investigate the effect of time on RNA disrup-
tion, A2780 cells were treated with 0.005 or 0.2 μM
paclitaxel or docetaxel for 24 to 72 h (Fig. 1a and c).
RNA disruption became detectable at 24 h but contin-
ued to increase up to 72 h. RDI values confirmed a
significant increase in RNA disruption for both pacli-
taxel- and docetaxel-treated samples over time (Fig. 1b
and d). The untreated (0 μM) control sample did not ex-
hibit abnormal bands on electropherograms and retained
a low RDI value at all time points.
The CaOV3 ovarian carcinoma cell line was also
treated with docetaxel to determine if other ovarian
cancer cell lines could exhibit taxane-induced RNA dis-
ruption. Using the same docetaxel doses as for A2780
cells, RNA disruption was observed in CaOV3 cells
(Fig. 1e) after 48 h of docetaxel treatment and disruption
was further increased at 72 h. There was a significant
increase in the amount of RNA disruption in both 0.005
and 0.2 μM docetaxel treated CaOV3 cells (Fig. 1f ) at 48
and 72 h.
Carboplatin induces dose dependent RNA disruption in
A2780 and CaOV3 cells
Carboplatin, a structurally distinct drug with a very
different mechanism of action from taxanes, required
a longer exposure time to induce RNA disruption in
A2780 and CaOV3 cells. Therefore, A2780 and CaOV3
cells were treated for 72 h with increasing doses of carbo-
platin. Figure 2a and b display RNA electropherograms
and RDI values of A2780 cells treated with 0.001 to
100 μM carboplatin. For A2780 cells, RNA disruption
became detectable and significantly higher beginning at
5 μM carboplatin. For CaOV3 cells, RNA disruption
was detectable at 10 μM carboplatin but RDI values did
not become significantly higher compared to untreated
cells until 50 and 100 μM carboplatin were used (Fig. 2c
and d).
Multiple chemotherapy agents induce RNA disruption in
breast and ovarian cancer cell lines
To investigate if RNA disruption can be induced by
multiple cytotoxic chemotherapy agents, with differing
mechanisms of action, A2780 ovarian and MDA-MB-
231 breast cancer cells were treated with a panel of
chemotherapy drugs. RNA disruption was induced in
A2780 cells by treatment with paclitaxel (TAX), doce-
taxel (DXL), carboplatin (CBN), cisplatin (CIS), etopo-
side (ETOP), vincristine (VIN), irinotecan (IRN) and
doxorubicin (DOX), as shown in the electropherogram in
Fig. 3a. In MDA-MB-231 cells, paclitaxel, docetaxel,
cisplatin, etoposide, doxorubicin and vincristine were
all capable of inducing RNA disruption (Fig. 3b). Fi-
nally, chemotherapy drug-induced RNA disruption was
observed in multiple breast (MCF-7, MDA-MB-231,
Table 1 Oligonucleotide probes for Northern blot analysis of rRNA fragments
Probe Source Complementary sequence used in probes Position in human a28S or b18S rRNA
28SCD1 Houge et al. (1995) [12] 5’-GAC TAA TAT GCT TAA ATT CAG CGG GTC GCC ACG TC-3’ 16–50
28SVR2 Nadano et al. (2000) [25] 5’-ACG TGT TAG ACT CCT TGG TCC GTG-3’ 1305–1328
28S1 He et al. (2012) [30] 5’-ACC CGG CGT TCG GTT CAT-3’ 1867–1884
28S4 He et al. (2012) [30] 5’-GCG GGC CTT CGC GAT GCT TTG TT-3’ 3617–3639
28S5 He et al. (2012) [30] 5’-ACC CAG AAG CAG GTC GTC TAC GAA TGG TTT AGC GCC AG-3’ 4913–4950
18S1 He et al. (2012) [30] 5’-GCA CCA GAC TTG CCC TCC-3’ 698–715
18S2 He et al. (2012) [30] 5’-GAA TAA CGC CGC CGC ATC-3’ 1200–1217
18S3 He et al. (2012) [30] 5’-CGG ACA TCT AAG GGC ATC ACA G-3’ 1594–1615
a28S rRNA sequence Genbank ID M11167.1
b18S rRNA sequence Genbank ID M10098.1

























































































































































































































Fig. 1 Dose and time-dependent ribosomal RNA disruption in response to taxanes. A2780 and CaOV3 cells were exposed to increasing concentrations
of either docetaxel (DXL) or paclitaxel (TAX) for times ranging from 24 to 72 h. Total RNA was isolated from cells following drug exposure and RNA
quality was analyzed by capillary electrophoresis. Electropherograms showing RNA mobility were converted to gel images using the Bioanalyzer
software. a Gel image of RNA from A2780 cells treated with paclitaxel. b RDI analysis of RNA isolated from paclitaxel treated A2780 cells. c Gel image
of RNA from A2780 cells treated with docetaxel. d RDI analysis of RNA isolated from docetaxel treated A2780 cells. e Gel image of RNA isolated from
CaOV3 cells treated with docetaxel. f RDI analysis of RNA isolated from CaOV3 cells treated with docetaxel
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SKBR3, BT474) and ovarian (A2780, CaOV3) cancer
cell lines following treatment with docetaxel (Fig. 3c),
demonstrating that RNA disruption is observed in mul-
tiple cell lines of different tissue origin (Figs. 1, 2, 3).
RNA disruption bands originate from the 28S rRNA
The abnormal RNA disruption bands that occur upon
chemotherapy drug exposure are smaller in molecular
weight than the 28S and/or 18S rRNAs. To determine
whether the abnormal bands originate from the 28S
and/or 18S rRNAs, Northern blotting experiments were
performed on total RNA prepared from A2780 cells after
incubation in the absence or presence of docetaxel for
up to 48 h (Fig. 4). Of the probes complementary to the
28S rRNA, only probe 28S-5 hybridized to RNA disrup-
tion bands (Fig. 4, Additional files 2 and 3). Figure 4a
shows hybridization of the 28S-5 probe to the 28S rRNA
and to two smaller bands computed to be 3012 nt and
1630 nt in length. Both of these RNA disruption bands
were derived from the 3’end of the 28S rRNA sequence,
given the location to which the 28S-5 probe binds within
the 28S rRNA (see Discussion). The diagram of the 28S
rRNA in Fig. 4b indicates the derivation of the 3012 nt
and 1630 nt bands upon RNA disruption. Three probes
were used to attempt to detect fragments derived from
the 18S rRNA, but none of the probes were able to
detect any fragments of the 18S rRNA after 48 h of
docetaxel treatment (Additional files 2 and 4).
RDI values reflect cellular sensitivity or resistance to
chemotherapy drugs
To investigate the relationship between drug sensitivity
and drug-induced RNA disruption, total RNA was isolated
from docetaxel-sensitive (A2780) and docetaxel-resistant
(A2780DXL) cells after treatment with 0.005 and 0.2 μM
docetaxel for 48 or 72 h. Consistent with their known
drug sensitivity using clonogenic assays [23], A2780 cells
exhibited a significantly higher RNA disruption index than
A2780DXL cells did (Fig. 5a). In keeping with the





















































































Fig. 2 Dose dependence of carboplatin-induced RNA disruption in A2780 and CaOV3 cells. A2780 and CaOV3 cells were treated with increasing
concentrations of carboplatin (CBN) for 72 h, the length of time required to detect the RNA disruption response to carboplatin. Total RNA was
isolated from cells following drug exposure and RNA quality was analyzed by capillary electrophoresis. a Gel image of RNA from A2780 cells
treated with carboplatin. b RDI analysis of RNA isolated from carboplatin treated A2780 cells. c Gel image of RNA from CaOV3 cells treated with
carboplatin. d RDI analysis of RNA isolated from carboplatin treated CaOV3 cells
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docetaxel-induced RNA degradation bands in sensitive
A2780 cells but not docetaxel-resistant A2780DXL cells
(Additional file 5A). Similarly, RDI values were signifi-
cantly higher in carboplatin-treated A2780 cells than in
similarly treated carboplatin-resistant A2780CBN cells
(Fig. 5b). Gel images of the electropherograms showed
greater numbers of RNA degradation bands in the A2780



























































































































Fig. 3 Multiple chemotherapy agents induce RNA disruption in breast and ovarian cancer cell lines. Multiple breast and ovarian cancer cell lines
were exposed to various chemotherapy agents and total RNA was isolated from the cells following drug exposure. a Gel image of total RNA
isolated from A2780 cells treated with multiple chemotherapy agents. All treatments were for 72 h, except carboplatin, which was treated for
120 h. b Gel image of RNA isolated from MDA-MB-231, a breast cancer cell line, following treatment with multiple chemotherapy agents. All
treatments were for 72 h, except for the control (0 μM) and cisplatin which were treated for 96 h. c Gel image of RNA isolated from various breast
(MCF-7, MB231, SKBR3, BT474) and ovarian cancer (A2780, CaOV3) cells following 72 h docetaxel treatment, except for MDA-MB-231-0 μM, from
which RNA was isolated after 96 h. Abbreviations: TAX-paclitaxel, DXL-docetaxel, CBN-carboplatin, CIS-cisplatin, ETOP-etoposide, VIN-vincristine,
IRN-irinotecan, DOX-doxorubicin
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file 5B). In a separate study by our laboratory, Armstrong
et al. demonstrated lack of cross resistance, using a clono-
genic assay, which showed that A2780DXL cells are sensi-
tive to killing by carboplatin and that A2780CBN cells are
sensitive to killing by docetaxel [23]. Using RDI analysis
we were able to confirm this response, as significantly
higher RDI values were observed in the treated resistant
cells when compared to the untreated resistant cells,
demonstrating sensitivity of the A2780DXL cells to carbo-
platin and of the A2780CBN cells to docetaxel (Fig. 5c
and d). RDA consistently reflected the above differential
drug sensitivities, by displaying higher RDI values and
RNA disruption bands in drug-sensitive cells (Additional
file 5A, B, C, D).
Concurrent induction of apoptosis and RNA disruption by
docetaxel
To assess whether docetaxel induces apoptosis and
whether this is concurrent with the induction of RNA
disruption, A2780 cells were treated with 0.2 μM doce-
taxel for varying times up to 72 h. Cells were stained
with annexin V-fluorescein isothiocyanate (annexin V-
FITC) and propidium iodide (PI) and analyzed by flow
cytometry (Fig. 6a). At 24 h there was a significant
- cleavage sites observed in A2780 cells treated with docetaxel












































28S CD1 28S VR2 28S-1 28S-4 28S-5
Fig. 4 Northern blot analysis of RNA isolated from A2780 cells treated with docetaxel. A2780 cells were treated with 0.2 μM docetaxel for 48 h
and total RNA was isolated. RNA was resolved by agarose gel electrophoresis and transferred to PVDF membranes for hybridization with the
32P-end-labeled oligonucleotide probe, 28S-5. a The panel on the left shows the agarose gel and the panel on the right shows the Northern
blot of the gel. RNA bands are indicated by arrows with the size of the band in nucleotides alongside. b A schematic diagram of the 28S rRNA
sequence showing conserved and variable regions, based on the structure of the 28S rRNA as defined by Gorski et al. (1987) [53] and Wakeman
et al. [28]. Location of the probes in the 28S rRNA sequence is shown above the diagram using arrows and the location of the cleavage sites and
resulting bands are shown below the diagram
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increase in the number of cells stained with annexin
V-FITC only, which persisted at 48 and 72 h, indicat-
ing that the cells were in early apoptosis. No increase
in PI staining was observed up to 72 h, suggesting
that cells had retained plasma membrane integrity
and had not undergone necrosis. Next, the effect of
docetaxel treatment on cell cycle progression was
investigated using PI staining of fixed cells following
8, 24, 48 and 72 h of docetaxel exposure (Fig. 6b). A
sub G1 peak, often associated with apoptotic bodies,
was evident in the docetaxel treated cells after 24 h,
and by 72 h, almost all the PI signal was in the sub
G1 peak. This shows that extended docetaxel treat-
ment generated cell fragments with less than a diploid
amount of DNA content, representing apoptotic bod-
ies or micronuclei. Finally, to see if DNA laddering (a
late apoptosis biomarker) also occurred, A2780 and Jurkat
cells were treated with or without docetaxel (A2780 cells)
or etoposide (Jurkat cells) for similar lengths of time.
Genomic DNA was prepared from the cells and resolved
by agarose gel electrophoresis (Fig. 6c). Interestingly,
docetaxel-treated A2780 cells did not show any evidence
of DNA fragmentation while the DNA from etoposide-
treated Jurkat cells was clearly degraded. To confirm that
A2780 cells treated with docetaxel were no longer viable
despite the lack of DNA degradation, a recovery assay was
performed to determine if docetaxel-treated A2780 cells
were capable of resuming growth when transferred into
drug-free cell culture medium. Following exposure to
0.005 or 0.2 μM docetaxel for up to 72 h, cells were re-
plated in fresh, drug-free medium and cultured for up to
96 additional hours (Fig. 7). Cells treated with 0.2 μM
docetaxel never recovered (regardless of incubation time),
while those treated with 0.005 μM docetaxel could recover
after 24 and 48 h of docetaxel exposure but not after 72 h
docetaxel exposure. When one relates these observations
to the extent of RNA disruption induced in A2780 cells
treated with 0.005 or 0.2 μM docetaxel over time (Fig. 1d),
it appears that cells can only tolerate a specific level of
RNA disruption (RDI = ~0.5), above which cells become
nonviable.
Caspase-3 activation and RNA disruption
To further support the induction of apoptosis in A2780
cells in response to docetaxel, we examined the effect of
docetaxel treatment on caspase-3 activity at 24, 48, and
72 h following treatment. Figure 8a shows that caspase-3
activity increased in response to docetaxel at 24 h and
this response persisted through 72 h. The possible con-
nection between docetaxel-induced caspase-3 activation
and RNA disruption was then investigated by treating















































































Fig. 5 Lack of RNA disruption response in drug resistant cells. A2780 and A2780DXL (resistant to docetaxel) cells were treated with 0, 0.005 and
0.2 μM docetaxel (DXL) for 48 and 72 h. RNA isolated from the cells was analyzed by capillary gel electrophoresis. A2780 and A2780CBN (resistant
to carboplatin) cells were treated with 0 and 10 μM carboplatin (CBN) for 72 h. To test for cross-resistance, A2780DXL cells were treated with 0
and 5 μM carboplatin while A2780CBN cells were treated with 0 and 0.2 μM docetaxel. RNA isolated from the cells was analyzed by capillary gel
electrophoresis. a RDI analysis of RNA isolated from A2780 and A2780DXL cells treated with docetaxel. b RDI analysis of RNA isolated from A2780
and A2780CBN cells treated with carboplatin. c RDI analysis of A2780DXL cells treated with 0 and 5 μM carboplatin. d RDI analysis of RNA isolated
from A2780CBN cells treated with 0 and 0.2 μM docetaxel
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48 hr
0 µM DXL 0.2 µM DXL
24 hr
0 µM DXL 0.2 µM DXL
8 hr













































































0 µM DXL 0.2 µM DXL
Fig. 6 (See legend on next page.)
Narendrula et al. BMC Cancer  (2016) 16:146 Page 10 of 17
the caspase-3 inhibitor (Q-DEVD-Oph). As shown in
Fig. 8b, suppression of caspase-3 activity by Q-DEVD-
Oph was evident beginning at 24 h after co-treatment
with docetaxel, but a statistically significant reduction in
caspase-3 activity was only apparent at 72 h (Fig. 8b).
Figure 8c depicts the RNA banding pattern for A2780
cells following docetaxel treatment for 72 h, with or
without Q-DEVD-Oph. The intact 28S and 18S rRNA
bands are indicated by arrows. Without the caspase-3
inhibitor (lane marked -), the original 28S and 18S rRNA
bands of untreated cells were reduced in intensity in the
presence of docetaxel, while the intensities of the abnor-
mal RNA disruption bands increased. When A2780 cells
were co-treated with both docetaxel and Q-DEVD-Oph
(lane marked +), the intensities of the 28S and 18S
rRNA bands were stronger, while the intensities of the
RNA disruption bands were weaker. RDI values for these
samples are shown in Fig. 8d, where cellular RNA from
docetaxel-treated cells without the caspase-3 inhibitor
had a significantly greater RDI value than cellular RNA
from docetaxel-treated cells in the presence of the
caspase-3 inhibitor, demonstrating that reduced RNA
disruption is concomitant with suppression of apoptosis
via caspase-3 inhibition.
Discussion
Previous studies have shown that a variety of apoptosis-
inducing agents with distinct mechanisms of action
(glucocorticoids, okadaic acid, tumor necrosis factor
(TNF), dexamethasone, a calcium ionophore and a tri-
cothecene mycotoxin) were able to induce an ordered,
apoptosis-associated rRNA degradation in several differ-
ent cell types, including plant cells and the unicellular
organism yeast [11–13, 15–17, 24]. However, this study is
the first to report the ability of structurally distinct cyto-
toxic chemotherapy agents with different mechanisms
of action to induce the formation of high molecular
weight rRNA degradation fragments (Figs. 1, 2 and 3), a
phenomenon we term “RNA disruption”. This suggests
that, despite contrasting structures and mechanisms of
action, different chemotherapy agents activate a com-
mon rRNA degradation mechanism. Moreover, chemo-
therapy induced RNA disruption was observed across
multiple ovarian and breast cancer cell lines, further
supporting the widespread nature of this phenomenon
(Fig. 3c).
We further observed that RNA disruption is both
dose- and time-dependent (Figs. 1 and 2). Moreover, the
extent of RNA disruption closely reflects cellular sensi-
tivity to chemotherapy agents (Fig. 5). RNA disruption
was observed to occur only in cell lines demonstrated to
have sensitivity to chemotherapy agents (as measured
using clonogenic assays) with no RNA disruption being
observed in derivative cell lines exhibiting resistance to
these agents (Fig. 5). We also show in this study that
there is a temporal relationship between induction of
apoptosis by docetaxel in A2780 cells and RNA disrup-
tion by this agent.
Significant RNA disruption occurred after 24 h expos-
ure to paclitaxel and docetaxel in A2780 cells and after
48 h in CaOV3 ovarian tumor cell lines treated with
docetaxel. RNA disruption was always maximal at the
longest incubation time (72 h) (Fig. 1). Carboplatin-
induced RNA disruption required a longer exposure
time for detection (72 h) and RDI values of carboplatin-
treated cells were significantly different from untreated
cells when a 50 μM drug concentration was applied to
both A2780 and CaOV3 cells (Fig. 2). The difference in
exposure time and concentration needed to induce RNA
disruption may be due to the different mechanisms of
action of the two drugs. Furthermore, the drugs produce
slightly different rRNA fragments between the 28S and
18S rRNA bands (Figs. 1 and 2), although a common
rRNA fragment of slightly greater mobility than the 18S
rRNA was generated by both agents. Differing RNA
fragmentation patterns were observed by Houge et al.
depending upon the apoptosis-inducing agent used and
the cell line being investigated. They observed a unique
cleavage site in the 28S rRNA in bovine endothelial
cells, although the RNA cleavage patterns in different
cell types were remarkably similar overall [12]. In yeast,
different apoptosis-inducing agents or treatments also
generated different patterns of rRNA degradation [16].
In another study by He et al. in murine macrophages,
rRNA cleavage was induced by the tricothecene myco-
toxin deoxynivalenol. The pattern observed by He et al.
contains a similar fragment just below the 18S rRNA
and contains three fragments in the region between
the 28S and 18S rRNA bands – similar to patterns
observed by Houge et al. [12]. In a study by Nadano
et al., two different apoptosis-inducing agents were used
in Jurkat and U937 cells to initiate rRNA fragmentation
(See figure on previous page.)
Fig. 6 Early and late markers of apoptosis in A2780 cells treated with 0.2 μM docetaxel.A2780 cells were treated with 0.2 μM docetaxel (DXL) for
8, 24, 48 and 72 h. a Cells were stained with annexin V-FITC and propidium iodide and analyzed by flow cytometry. Scatter plots of stained cells
at each time point are shown. b A2780 cells were stained with propidium iodide only and analyzed by flow cytometry. Histograms of stained
cells are shown for each time point. c DNA laddering in A2780 cells treated with 0 and 0.2 μM docetaxel for times ranging from 2 to 72 h. Jurkat
cells were treated with 5 and 30 μM etoposide as a positive control. DNA was isolated from cells at each time point and analyzed by agarose gel
electrophoresis. A representative ethidium bromide stained gel is shown
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(Fas ligand and TNFα), producing a pattern with a band
just below the 18S rRNA but with only one clearly dis-
cernable band in the region between the 28S and 18S
rRNAs [25]. A very different RNA banding pattern was
demonstrated by King et al. in S49 cells treated with
several different apoptotic stimuli. No degradation band
below the 18S rRNA was observed and all 5 degradation
bands were derived from the 5’-end of the 28S rRNA [17].
In our study, the RNA disruption pattern generated by
taxane treatment is the same in the A2780 and CaOV3
cells, composed of a major fragment below the 18S rRNA
band and two major fragments between the 28S and 18S
rRNA bands (Fig. 1). Carboplatin treatment also generated
a fragment just below the 18S rRNA band in both A2780
and CaOV3 cells but appeared to generate multiple
fragments in the region between the 28S and 18S rRNA
(Fig. 2). Therefore, ordered RNA disruption appears to
occur in different ways depending on the cell type and
stimulus, suggesting varying mechanisms or reaction
kinetics for RNA disruption in cells, depending upon
the cell line and/or the RNA disruption-inducing agent.
In this study, we have documented that the ability of
specific chemotherapy agents to induce cell death/
growth arrest in a clonogenic assay is also reflected in
their ability to induce RNA disruption in tumor cells in
vitro (Fig. 5). Our data thus suggests that RNA
disruption by chemotherapy agents accurately reflects
cellular drug sensitivity and drug resistance (as mea-
sured using the highly sensitive clonogenic assay). This
reinforces the usefulness of the RNA disruption assay
(RDA) as a technique for quantifying response to cyto-
toxic agents such as chemotherapy drugs. Moreover,
the RNA disruption assay appears to be equivalent in
sensitivity to the clonogenic assay in evaluating response
to treatment, is much less labor intensive, is amenable to
high throughput approaches, and requires less time to
obtain assay results. It may thus represent a valuable tool
for drug discovery. The observations of our current study
(See figure on previous page.)
Fig. 7 Recovery and proliferation of A2780 cells following docetaxel treatment. In order to assess whether the A2780 cells treated with docetaxel
(DXL) that show RNA degradation are able to recover and proliferate, cells were treated with 0, 0.005 or 0.2 μM docetaxel for 24, 48 and 72 h.
Following the treatment end point, cells were collected and replated in fresh drug-free medium, and their proliferation was assessed following
recovery for 24, 48, 72 and 96 h of replating. a Recovery of cells after 24 h treatment. b Recovery after 48 h drug treatment. c Recovery following













































































Fig. 8 Caspase-3 activation is associated with RNA disruption after docetaxel treatment in A2780 cells. A2780 cells were treated with 0.2 μM
docetaxel (DXL) for 24, 48 or 72 h. a Caspase-3 activity, assayed using a DEVD substrate, in lysates from A2780 cells. b Effect of a caspase-3 inhibitor
on caspase-3 activation in lysates from docetaxel treated A2780 cells. c Gel image of RNA disruption in A2780 cells treated with docetaxel, in the
presence (+) or absence (−) of caspase-3 inhibitor (Q-DEVD-Oph). d RDI analysis of RNA from A2780 cells treated with docetaxel for 72 h, with and
without the caspase-3 inhibitor
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also provide in vitro confirmation of the association of
RNA disruption with response to chemotherapy in pa-
tients with locally advanced breast cancer [18, 20].
Northern blots of total RNA isolated from A2780
cells treated with docetaxel were used to identify the
approximate origins of the RNA disruption bands. As
described above, the 28S-5 probe hybridized to the full-
length 28S rRNA and to two 28S rRNA fragments –
one migrating faster than the full-length 18S rRNA
(1,870 nt) and one migrating between the intact 28S
(5,025 nt) and 18S rRNA bands (Fig. 4a). Their sizes
were determined to be 1,630 nt and 3,012 nt respect-
ively (although these calculated sizes should be inter-
preted as approximate values). Since both fragments
were detected by the most 3’ probe (28S-5), they must
have been derived from the 3’-end of the 28S rRNA,
with the smaller fragment derived from the larger
(Fig. 4b). The size of 3,012 nt for the larger fragment
suggests that there must be a cleavage site within the
full-length 28S rRNA sequence approximately 2,013 nt
from the 5’ end of the molecule (5,025 minus 3,012 nt).
The smaller fragment (1,630 nt) indicates another
cleavage site located 3,395 nt from the 5’ end of the
molecule (5,025 minus 1,630 nt; see Fig. 4b). This inter-
pretation suggests that another 28S rRNA fragment of
about 2,013 nt is produced upon docetaxel treatment
(2,013 nucleotides from the 5’-end of the molecule),
which was not detected by any of the other probes (28S
CD1, 28S VR2, and 28S-1). The reason for this is not
clear. It is possible that this 2,013 nt fragment, when
generated, is not stable and/or is subjected immediately
to RNase digestion. In support of this idea, Mroczek
and Kufel report that some rRNA fragments are sus-
ceptible to digestion by the exosome while other
fragments are not [16]. The cleavage site at 3,395 nt
from the 5’ end of the 28S rRNA is located in variable
region (expansion segment) 8, which has been identi-
fied as containing an RNase cleavage site in prior
studies [12, 24, 25]. The nucleotide sequence of variable
region 8 was correlated by Wakeman et al. with struc-
tural features of the human 28S rRNA [28]. Based on
this analysis, a double loop structure in the 3’ end of
the 28S rRNA contains cleavage sites identified by He
et al. [24] and Houge et al. [12] which are located in
the second loop of variable or expansion region 8. The
estimated cleavage site in the 3’-end of the 28S rRNA
from our data is also located in this loop, supporting
the identification of this location as an important site
vulnerable to cleavage in response to various cytotoxic
stressors. In this study, fragments derived from the 18S
rRNA were not detected using three different probes
recognizing 18S rRNA sequences (Additional file 4),
which indicates that the 18S rRNA was not cleaved
within the 48 h period of exposure to docetaxel. Lack
of cleavage of the 18S rRNA was reported in several
studies, while others show cleavage of both the 18S and
28S rRNAs [11, 12, 17, 24, 25]. These differences in the
origins of RNA disruption bands may relate to the
agent/stressor inducing rRNA degradation and/or the
time of incubation. For example, we have observed the
loss of the 18S rRNA band on RNA electropherograms
of A2780 cells incubated with taxanes, especially at the
later time point of 72 h (Fig. 1a, c).
The degradation of rRNA by cytotoxic stressors has
been shown to correlate with the induction of apoptosis
in several cell systems [11, 12, 16, 17, 24, 25, 29]. In the
current study, the chemotherapy drug docetaxel appeared
to induce apoptosis in A2780 cells, as evidenced by ele-
vated annexin V binding (peaking at 72 h; Fig. 6a),
increased caspase-3 activity (peaking at 24 h; Fig. 8a), and
a dramatic rise in the amount of apoptotic bodies with a
sub-G1 DNA content (peaking at 72 h; Fig. 6b). RNA
disruption was also induced by docetaxel in A2780 cells
and was highest at 72 h in this study (Fig. 1). This
suggested a temporal correlation between the induction of
apoptosis and RNA disruption. The association of RNA
disruption with apoptosis is also suggested by our findings
that the cell permeable caspase inhibitor Q-DEVD-Oph
was able to partially suppress both caspase-3 activity and
docetaxel-induced RNA disruption (Fig. 8b, c, and d). This
is consistent with previous findings that apoptosis as-
sociated rRNA degradation is dependent upon caspase
activation [24, 30–34]. However, apoptosis can occur
without RNA disruption [35] and rRNA cleavage has
been observed in the absence of caspase- and BCL-2
dependent apoptosis [16, 17, 25, 36], suggesting that
these two processes can occur independently of each
other. Moreover, there is increasing evidence that cas-
pases (such as caspase-3 and caspase-7) may play a
role in cell cycle progression independent of their role
in promoting cell death [37, 38]. Similarly, the role of
caspases in RNA disruption may be unrelated to their
role in apoptosis. Our results also show that doce-
taxel treatment of A2780 cells did not promote DNA
laddering (Fig. 6c), a common phenomenon associated
with apoptosis in many cell types. However, lack of
DNA degradation during apoptosis has been reported
in a number of studies [35, 39–41]. Our findings sug-
gest that docetaxel-induced apoptosis in A2780 cells
lacks a mechanism for activating DNA fragmentation,
while the RNA fragmentation mechanism is not blocked.
It is also worth noting that additional studies in our
laboratory indicated that apoptotic biomarkers (cleaved
caspase-3 and PARP cleavage) wane considerably by 72 h
(Additional file 6), while RNA disruption products persist
(Figs. 1, 2, and 3). RNA disruption may thus be a pref-
erable biomarker for identifying cells/tissues/patients
responding to chemotherapy [18, 20].
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At present, the mechanism for chemotherapy-dependent
RNA disruption is unknown. A mechanism for rRNA deg-
radation induced by nutritional deficit, called ribophagy,
has been described and shown to be distinct from general
autophagy [9]. Specific ubiquitination and deubiquitination
can protect against or promote ribophagy, indicating an
important role for the ubiquitin status of the ribosome in
determining susceptibility to ribophagy [9, 42]. However,
chemotherapy drug–induced rRNA disruption occurs with-
out any known nutritional deficit and is irreversible after
sufficient rRNA disruption has occurred, while ribophagy
appears to promote survival during extended nutritional
deprivation. A second mechanism for the selective removal
of non-functional ribosomes, non-functional rRNA Decay
(NRD), has also been described [3, 4, 8, 43]. While ubiqui-
tin also plays a role in NRD, different proteins from those
involved in ribophagy appear to be involved, including
factors known to act in DNA repair. While we cannot rule
out either ribophagy or NRD at this time as mechanisms of
ribosomal decay contributing to rRNA disruption, it is
worth noting that the generation of specific high molecular
weight rRNA fragments has not yet been reported as asso-
ciated with either ribophagy or NRD.
Another possible mechanism may involve the recently
described ability of chemotherapy agents such as doce-
taxel and doxorubicin to induce TNFα production and
release from tumor cells [44]. This could, in turn, result
in the activation of a specific receptor for TNFα (TNFR1)
known to induce apoptosis through the activation of
specific caspases [45, 46]. Consistent with this view, both
TNFα and Fas ligand have been shown to induce rRNA
degradation in human leukemia cells [25]. Furthermore,
chemotherapy agents such as docetaxel and doxorubicin
are also well known to induce reactive oxygen species
(ROS) in tumor cells, which, in turn, can activate caspases
and/or apoptosis [47, 48]. ROS can directly promote
the phosphorylation and ubiquitination of Bcl-2 family
proteins, resulting in cytochrome c release from mito-
chondria and caspase activation. Mitochondria appear
to be both the source and target of ROS [49–51]. In-
deed, Mroczek and Kufel present strong evidence that
apoptosis-associated rRNA fragmentation in yeast is
correlated with ROS levels, cellular response to oxida-
tive stress, and reduced mitochondrial activity, but not
caspase activity [16]. In tumor cells the mechanism
could differ somewhat, considering that caspases could
be activated by TNFα or ROS generation, resulting in
RNA disruption. The evidence provided in the current
study demonstrates that a caspase inhibitor significantly
reduces docetaxel-induced RNA disruption.
In terms of possible enzymes facilitating RNA disruption,
it is highly likely that they are RNA hydrolases (RNases).
These RNases could be homologs of RNases recently iden-
tified to play a role in stress-induced rRNA degradation in
yeast [52]. These investigators identified several RNases as-
sociated with stress-induced rRNA fragmentation in yeast,
the mammalian homologs of which would be the exonucle-
ase XRN1, an endonuclease involved in rRNA processing
(MRP), an RNase associated with the nuclear and cytoplas-
mic human exosomes (PM/Scl-100), and the mitochondrial
nuclease Endonuclease G. Further studies are planned to
elucidate the precise mechanism(s) involved in RNA dis-
ruption by cytotoxic chemotherapy drugs.
Conclusions
In this study, we show that RNA disruption can be in-
duced in various cell types by structurally distinct chemo-
therapy agents with contrasting mechanisms of action in a
dose- and time-dependent manner. The disruption frag-
ments (at least for docetaxel) initially stem from cleavages
within the expansion segments (variable regions) of the
28S rRNA. The extent of RNA disruption observed in
cells reflects their sensitivity (or lack thereof) to chemo-
therapy drugs and cells can only tolerate a specific level of
RNA disruption, above which they become nonviable.
Moreover, while the induction of RNA disruption is tem-
porally correlated with the induction of apoptosis, RNA
fragmentation products accumulate over time, while
apoptotic biomarkers wane. RNA disruption is associated
with caspase activation and a known caspase-3 inhibitor
can substantially reduce RNA disruption by docetaxel.
The link between drug sensitivity in cell lines (previously
assessed by clonogenic assay) and drug-induced RNA dis-
ruption strongly support our recent clinical findings that
high tumor RNA disruption is associated with tumor
sensitivity to drug, expressed as a pathologic complete
response and enhanced disease-free survival after neoad-
juvant chemotherapy in patients with locally advanced or
inflammatory breast cancer [20]. RNA disruption thus ap-
pears to be a highly reproducible, natural phenomenon
observed in tumor cells and represents a powerful new in
vitro and in vivo biomarker of chemotherapy response.
Additional files
Additional file 1: Change in total RNA concentration as a result of
paclitaxel treatment. Total RNA was isolated from A2780 cells treated
with paclitaxel for 24, 48 and 72 h which were assessed for changes in
both, quantity as well as integrity. In addition to the presence of unique
bands, a significant decrease in RNA concentration is observed as a result
of drug treatment which appears to be both dose and time-dependent.
(PPTX 84 kb)
Additional file 2: Schematic diagrams of the 28S and 18S human rRNA
structures, showing locations of the oligonucleotide probes for the
Northern blots. Diagrams of the 28S and 18S rRNA and the location of
oligonucleotide probes hybridization used for Northern blot analysis.
Regions of conserved sequence and variable (expansion) regions are
shown by color blocks in the diagrams. A. Human 28S rRNA structure
(5025 nt) with the locations of oligonucleotide probes hybridizing to the
28S rRNA indicated by the arrows. B. Human 18S rRNA structure (1868 nt)
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with the locations of probes hybridizing to the 18S rRNA are indicated by
the arrows. (PPTX 36 kb)
Additional file 3: Northern blots of total A2780 RNA hybridized with
28S probes. Panels on the left side show an RNA gel and panels on the
right side show corresponding membranes after transfer and blotting.
RNA isolated from untreated cells is in lanes marked (-) while RNA
isolated from 48 h 0.2 μM docetaxel treated cells is in lanes marked (+).
Sizes of RNA bands on gels are shown in nucleotide length (nt) to the
left of the figure with arrows indicating each band. Sizes of hybridization
targets of probes are shown in nucleotides to the right of the figures
with arrows indicating each hybridization target. A. Northern blot results
using the 28S-1 probe. B. Northern blot results using the 28S-4 probe.
C. Northern blot results using the 28S CD1 probe. D. Northern blot results
using the 28S VR2 probe. (PPTX 407 kb)
Additional file 4: Northern blots of total A2780 RNA hybridized with
18S probes. Panels on the left side show an RNA gel and panels on the
right side show corresponding membranes after transfer and blotting.
RNA isolated from untreated cells is in lanes marked (-) while RNA
isolated from 48 h 0.2 μM docetaxel treated cells is in lanes marked (+).
Sizes of RNA bands on gels are shown in nucleotide length (nt) to the
left of the figure with arrows indicating each band. Sizes of hybridization
targets of probes are shown in nucleotides to the right of the figures
with arrows indicating each hybridization target. A. Northern blot results
using the 18S-1 probe. B. Northern blot results using the 18S-2 probe.
C. Northern blot results using the 18S-3 probe. (PPTX 410 kb)
Additional file 5: RNA disruption response in drug resistant cells treated
with chemotherapy agents. The gel images shown in this figure correspond
to the RDI data shown in Fig. 5. A. RNA disruption bands occur in the A2780
cells treated with 0.005 μM or 0.2 μM docetaxel (DXL) for 48 or 72 h. The
RNA disruption bands are absent in the RNA isolated from the resistant
A2780DXL cells treated with either concentration of docetaxel for either 48
or 72 h. B. Gel image of the RNA isolated from A2780 and A2780CBN cells
treated with carboplatin, which show the presence of RNA disruption bands
in the A2780 cells treated with 10 μM carboplatin for 72 h but display
absence of disruption bands in the resistant A2780CBN line. C. Gel image of
RNA isolated from A2780DXL cells treated with 5 μM carboplatin for 72 h,
showing the presence of unique bands as a result of treatment. D. Gel
image of RNA isolated from A2780CBN cells treated with 0.2 μM docetaxel
for 48 h, which shows RNA disruption bands. (PPTX 307 kb)
Additional file 6: Immunoblots of apoptotic proteins in docetaxel
treated A2780 cells. A2780 cells were untreated or treated with 0.2 μM
docetaxel for 24, 48, or 72 h. Protein lysates were prepared from the cells,
resolved by SDS-PAGE, and transferred to polyvinylidene difluoride (PVDF)
membranes. Immunoblotting was performed antibodies against full
length caspase 3, cleaved caspase 3, Parp-1 and the loading controls
GAPDH and β-actin. Primary antibodies for caspase-3 (3G2), PARP-1
(46D11) and GAPDH (14C10) were from Cell Signaling Technology, Inc.
(New England Biolabs, Ltd., Whitby, ON, CA) while HRP-conjugated
anti-mouse and –rabbit IgG secondary antibodies were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). The Parp-1 antibody detected
both full length and cleaved Parp-1. A. Immunoblot showing full length
caspase 3. B. Immunoblot showing cleaved caspase 3. B. Immunoblot
showing both full length and cleaved Parp-1. C. Immunoblot showing
GAPDH. D. Immunoblot showing β-actin. (PPTX 110 kb)
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